Fingerprint
Dive into the research topics of 'Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten, Alex A. Adjei, Robert Millham, Brett E. Houk, Gary Borzillo, Kristen Pierce, Zev A. Wainberg, Patricia M. LoRusso
Research output: Contribution to journal › Article › peer-review
53
Scopus
citations